Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Status Recruiting

Clinical Trial Summary

Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients. Morerover, molecular targeting agents does not show clear efficacy in EC up to now. Nowadays, the pace of development of cancer immunotherapies is accelerating. Clinical evidence of the efficacy of immune checkpoint inhibitors and adoptive immunotherapies herald the onset of a new era in cancer immunotherapy. There have also been recent developments to provide a promising frontier in extending the use of immunotherpay or targeting agents to radiotherapy. The purpose of this study was to explore the optimal treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04821778
Study type	Interventional
Source	Chinese Academy of Medical Sciences
Contact	Xin Wang, MD
Phone	+861013311583220
Email	beryl_wx2000@163.com
Status	Recruiting
Phase	Phase 3
Start date	January 1, 2002
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06376604` - Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies	N/A
Completed	`NCT03753542` - Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy	N/A
Not yet recruiting	`NCT05022628` - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis	Phase 4
Completed	`NCT04207359` - Effects of Creatine Supplementation in Breast Cancer Survivors	N/A
Active, not recruiting	`NCT04489173` - TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer	Phase 2
Completed	`NCT04173195` - Comfort Talk (CT) During Outpatient Chemotherapy	N/A
Recruiting	`NCT06041477` - Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC	Phase 3
Recruiting	`NCT05014399` - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Recruiting	`NCT03275194` - HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy	Phase 2
Recruiting	`NCT04808466` - Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy	Phase 2
Recruiting	`NCT06421610` - OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.	Phase 1
Completed	`NCT05131490` - Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients	N/A
Completed	`NCT04118322` - The Effect of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy	N/A
Recruiting	`NCT06043999` - Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients	N/A
Recruiting	`NCT05515796` - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors	Phase 2
Not yet recruiting	`NCT04845490` - Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy	Phase 2
Recruiting	`NCT04989985` - S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma	Phase 2
Recruiting	`NCT05424692` - Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer	N/A
Recruiting	`NCT05992337` - New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Enrolling by invitation	`NCT04027478` - Can Fasting Decrease the Side Effects of Chemotherapy?	N/A